HILDEN, Germany, & GERMANTOWN, Md., Jun 21, 2021--QIAGEN launches dedicated CRISPR products for rapid and simplified analysis of gene-editing experiments
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QIAGEN's (QGEN) therascreen KRAS kit to be used with LUMAKRAS is claimed to provide clinicians with a wide range of biomarker testing options, critical to patients with NSCLC.